| domain | established finding | evidence type | confidence/limitations |
|---|---|---|---|
| Inheritance / causal gene | Disease is resolved as an autosomal-recessive inborn error of immunity caused by biallelic loss-of-function variants in **FNIP1**; authoritative reviews/classifications describe FNIP1 deficiency as a syndromic predominantly antibody/B-cell defect with cardiomyopathy/pre-excitation features (pqac-00000008, pqac-00000009) | Human disease reviews/classification; mechanistic support from mouse genetics | Moderate-high confidence for gene-disease relationship; exact OMIM/MONDO row and full primary human case details were not directly retrievable in available evidence |
| Hallmark immune phenotype | Core immune phenotype is **B-cell deficiency/agammaglobulinemia or severe antibody deficiency**, with an early block in B-cell development inferred from human disease reviews and directly demonstrated in Fnip1-deficient mice (pqac-00000008, pqac-00000009, pqac-00000010, pqac-00000011, pqac-00000013) | Human reviews plus primary mouse/in vitro mechanistic studies | High confidence for B-cell developmental defect; frequencies, infection spectrum, and exact immunoglobulin values in humans unavailable from retrieved primary human text |
| Cardiac phenotype | Human FNIP1 deficiency is repeatedly summarized as associated with **hypertrophic cardiomyopathy** and sometimes **pre-excitation syndrome**; mouse Fnip1 loss causes left-ventricular hypertrophy/cardiomyopathy with glycogen accumulation, supporting biological plausibility (pqac-00000000, pqac-00000001, pqac-00000006, pqac-00000012) | Human review summaries; primary mouse cardiovascular phenotype | Moderate confidence for human HCM association; patient-level echocardiographic/ECG details were not available in accessible case reports |
| Mechanism / pathophysiology | FNIP1 is a regulator within the **FLCN–FNIP1–AMPK–mTORC1** network; in B-cell progenitors, Fnip1 deficiency causes inappropriate mTOR lysosomal localization, increased apoptosis under amino-acid deprivation, increased nuclear **TFE3**, increased lysosome function, and increased autophagic flux. Mouse data also support elevated AMPK activity and tissue-specific metabolic dysregulation in heart and skeletal muscle (pqac-00000000, pqac-00000002, pqac-00000003, pqac-00000010) | Primary mouse and cell-mechanistic studies; review synthesis | High confidence for pathway involvement in model systems; direct human tissue validation remains limited |
| Diagnosis | Practical diagnosis is by **genetic testing identifying biallelic FNIP1 variants** in a patient with severe B-cell/antibody deficiency plus syndromic features such as HCM/pre-excitation; classification papers recognize FNIP1 among novel monogenic IEIs (pqac-00000008, pqac-00000009) | Human classification/review evidence | Moderate confidence; no disease-specific diagnostic criteria, biomarker thresholds, or validated screening algorithm were retrieved |
| Management / trials | No disease-specific interventional trials were found. Management in the literature base is supportive and extrapolated from phenotype: immunoglobulin replacement/infection prevention for antibody deficiency and standard cardiology surveillance/management for HCM or conduction disease (supported indirectly by disease classification and absence of trials) (pqac-00000008, pqac-00000009) | Review/classification evidence plus negative clinical-trial search | Low-moderate confidence for disease-specific efficacy because direct outcome studies were not retrieved |
| Epidemiology | Condition appears **ultra-rare**, reported only in a very small number of families/patients in reviews; no prevalence or incidence estimates were available from the retrieved evidence (pqac-00000008, pqac-00000009) | Human review summaries | Low confidence for numeric epidemiology because exact counts and denominators were not available in accessible primary sources |
| Mouse model | Fnip1 mutant/knockout mice recapitulate major disease axes: **early B-cell developmental arrest**, reduced/absent peripheral B cells, marginal-zone B-cell sensitivity, **cardiomyopathy/LV hypertrophy**, glycogen accumulation, and altered skeletal-muscle metabolism/AMPK signaling (pqac-00000000, pqac-00000001, pqac-00000004, pqac-00000006, pqac-00000011, pqac-00000012, pqac-00000013) | Primary animal model evidence | High confidence; strong mechanistic relevance, though murine phenotypes cannot substitute for full human natural-history data |
| Evidence gaps | Exact patient variants, ages, sex distribution, penetrance, prognosis, and treatment responses were not established in the retrieved accessible evidence and should not be inferred without the primary human case series/case reports (pqac-00000008, pqac-00000009) | Evidence-quality assessment | High confidence that these are current evidence gaps in the accessible corpus |


*Table: This table summarizes the strongest currently retrievable evidence for Immunodeficiency 93 with hypertrophic cardiomyopathy, focusing on established findings and explicit limitations. It is useful as a compact knowledge-base scaffold when primary human case details are sparse or inaccessible.*